CD274 and non-small cell lung carcinoma: The assay was originally developed for use with clinical trials with nivolumab and was approved as a complementary diagnostic device for second-line treatment of NSCLC, as patients treated with nivolumab demonstrated increased response rate regardless of PD-L1 status (96).